Ocuphire Pharma, Inc. stock is down -4.44% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 February’s closed higher than January.
Ocuphire Pharma, Inc. focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, which is in Phase III clinical trial for dim light or night vision disturbances. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!